(800) 424-6690

Submit Your Information for the Elanco Animal Health Lawsuit

Lead Plaintiff Deadline is December 6, 2024.

If you purchased or acquired Elanco Animal Health securities between November 7, 2023 and June 26, 2024, please contact Berger Montague using the form below.

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of Elanco Animal Health?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive update from Berger Montague

Thank you! Your form has been successfully submitted.

About the Case

In November 2023, Elanco Animal Health set a timeline for U.S. approval by the Food and Drug Administration of both Zenrelia and Credelio Quattro in the first half of 2024. In May 2024, Elanco set a timeline for U.S. approval and commercial launch of Zenrelia in third quarter of 2024, as well as approval of Credelio Quattro in the third quarter of 2024, with a commercial launch set for the fourth quarter of 2024.

On June 27, 2024, the Company issued an update on FDA approval timelines for Zenrelia and Credelio Quattro, indicating that Elanco expected the U.S. label for Zenrelia to include a boxed safety warning which the Company believed would “slow the product adoption curve in the U.S.” and initially limit the number of days Zenrelia could safely be administered to dogs by approximately 25%. Further, Elanco stated that it was now expecting Zenrelia to receive FDA approval in the third quarter of 2024, leading to a potential commercial launch in the fourth quarter of 2024, and that Credelio Quattro is expected to receive FDA approval in the fourth quarter of 2024.

On this news, Elanco's stock price fell $3.69 per share, or 20%, to close at $14.28 per share on June 27, 2024.

Investors who purchased or acquired Elanco securities between November 7, 2023 and June 26, 2024, may no later than December 6, 2024, seek to be appointed as a lead plaintiff representative of the class.